Clinical trials: CGA
Prostate Cancer
Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
The aim of the study is to compare in an exploratory fashion the efficacy on progression-free survival of lanreotide in addition to non steroidal anti androgens and LHRH-a in non metastatic castrate resistant prostate cancer…
- Trial name
- POSEIDON (NCT01313273)
- Testing
- Lanreotide, non steroidal anti androgens and LHRH-a, Non steroidal anti androgens and LHRH-a
- Where
- Italy
- Volunteers
- 3 people
- Sponsor
- Ipsen
ECL-cell Hyperplasia, Parietal-cell Hyperplasia
Effect of Netazepide on Omeprazole-induced Changes in Chromogranin A and Gastrin
Hypergastrinaemia induced by proton pump inhibitor (PPI) treatment is reported to cause ECL-cell and parietal-cell hyperplasia, and rebound hyperacidity and dyspepsia after PPI withdrawal.
- Conditions
- ECL-cell Hyperplasia, Parietal-cell Hyperplasia, Rebound Hyperacidity, Dyspepsia
- Trial name
- NCT02620696
- Testing
- netazepide
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Gastric Neoplasms, Pancreatic Neoplasms
Chromogranin A as Blood Marker in Cancer Patients
Gastroentero-pancreatic neuroendocrine tumors (GEP-NETs) are a heterogenous group of neoplasms that arise from enterochromaffin cells of the gastrointestinal (GI) tract and pancreas. They account for 50-70% of all incident NETs.
- Conditions
- Gastric Neoplasms, Pancreatic Neoplasms, Small Intestinal Neoplasms, Colorectal Neoplasms
- Trial name
- NCT03817866
- Testing
- BRAHMS CgA II KRYPTOR
- Where
- 4 sites in United States, Germany
- Volunteers
- 175 people
- Sponsor
- Brahms AG
Prostate Cancer
Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients
The present study will provide information on whether the somatostatin analog, octreotide acetate, could have an inhibitory effect on circulating chromogranin A.
- Trial name
- NCT00166725
- Testing
- Octreotide LAR
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Novartis